ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10629	Companies
225888	Keywords
154416	Articles
119531	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 06/03/2026 at 20:19, 20 days 19 hours ago

OSE Immunotherapeutics publie ses résultats financiers consolidés audités pour l’exercice 2025 et annonce le dépôt de son Document d’Enregistrement Universel 2025
OSE Immunotherapeutics publie ses résultats financiers consolidés audités pour l’exercice 2025 et annonce le dépôt de son Document d’Enregistrement Universel 2025

Résultats Financiers Trésorerie Document D’enregistrement Universel OSE Immunotherapeutics Audités
PRESS RELEASE

published on 06/03/2026 at 20:19, 20 days 19 hours ago

OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
OSE Immunotherapeutics reports full year 2025 audited consolidated financial results and filing of 2025 Universal Registration Document, confirming cash runway with IRIS Financing

Universal Registration Document OSE Immunotherapeutics Cash Runway 2025 Financial Results IRIS Financing
BRIEF

published on 05/28/2026 at 21:09, 26 days 18 hours ago

OSE Immunotherapeutics obtient un financement relais flexible en fonds propres

Plan Stratégique Investisseurs Institutionnels Développement Clinique Émission D'actions Financement Flexible
BRIEF

published on 05/28/2026 at 21:09, 26 days 18 hours ago

OSE Immunotherapeutics Secures Flexible Bridge Equity Financing

Strategic Plan Clinical Development Institutional Investors Share Issuance Flexible Financing
PRESS RELEASE

published on 05/28/2026 at 21:04, 26 days 18 hours ago

OSE Immunotherapeutics met en place un financement relais flexible en fonds propres
OSE Immunotherapeutics lance un financement relais flexible en fonds propres avec IRIS Capital Investment pour un montant pouvant atteindre 19,3 millions d'euros sur 24 mois, prolongeant ainsi son horizon de trésorerie jusqu'à fin décembre 2026

Financement Fonds Propres OSE Immunotherapeutics Horizon De Trésorerie IRIS Capital Investment
PRESS RELEASE

published on 05/28/2026 at 21:04, 26 days 18 hours ago

OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
OSE Immunotherapeutics announces a flexible bridge equity financing with IRIS Capital Investment to raise €19.3 million, extending cash runway to December 2026 as part of a global financing strategy

OSE Immunotherapeutics Cash Runway Extension Bridge Equity Financing IRIS Capital Investment Global Financing Strategy
BRIEF

published on 05/22/2026 at 07:35, 1 month 2 days ago

OSE Immunotherapeutics Announces Positive Results in Ovarian Cancer Trial

Ovarian Cancer Clinical Trial Results OSE Immunotherapeutics Tedopi® TEDOVA Phase 2
BRIEF

published on 05/22/2026 at 07:35, 1 month 2 days ago

OSE Immunotherapeutics annonce des résultats positifs dans un essai clinique sur le cancer de l'ovaire

Résultats Des Essais Cliniques Tedopi® Immunothérapies OSE Cancer De L'ovaire Phase 2 De TEDOVA
PRESS RELEASE

published on 05/22/2026 at 07:30, 1 month 2 days ago

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
OSE Immunotherapeutics announces positive topline results from TEDOVA Phase 2 trial with Tedopi® in recurrent ovarian cancer, presenting at ASCO 2026. Combination with pembrolizumab improves progression-free survival

OSE Immunotherapeutics Tedopi TEDOVA Phase 2 ASCO 2026 Recurrent Ovarian Cancer
BRIEF

published on 04/30/2026 at 07:35, 1 month 24 days ago

OSE Immunotherapeutics: 2025 Financial Review and 2026 Outlook

Strategic Partnerships OSE Immunotherapeutics 2025 Financial Results Tedopi® Cash Flow 2026

Accesswire

Published on 06/24/2026 at 14:45, 50 minutes ago

Amdocs Selected by Three Scandinavia to Support Customer Engagement Transformation Across Nordic Markets
Published on 06/24/2026 at 14:00, 1 hour 35 minutes ago

GameSquare and U.S. Army Partner for Soldier Showdown 8, Presented by USAA
Published on 06/24/2026 at 14:00, 1 hour 35 minutes ago

Adcore Announces Voting Results from Annual Shareholders Meeting
Published on 06/24/2026 at 13:05, 2 hours 30 minutes ago

Faraday Copper Reports Drill Results Including Near-Surface Copper Mineralization in the American Eagle Area
Published on 06/24/2026 at 13:00, 2 hours 35 minutes ago

Aston Bay Provides Update on the Storm Copper Project - Advancing Towards Development

View all ACCESSWIRE

EQS Group

Published on 06/24/2026 at 15:20, 15 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 06/24/2026 at 15:20, 15 minutes ago

Form 8.3 - The Vanguard Group, Inc.: IP Group plc
Published on 06/24/2026 at 15:19, 16 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 06/24/2026 at 15:18, 17 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Forward Industries Inc.
Published on 06/24/2026 at 15:18, 17 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc

Les Echos

Published on 06/24/2026 at 09:30, 6 hours 5 minutes ago

CP HOPENING - Le 1er Baromètre “Libéralités - Grande Transmission”
Published on 06/23/2026 at 19:47, 19 hours 47 minutes ago

GROUPE SFPI: reorganisation de la Direction Générale
Published on 06/23/2026 at 19:47, 19 hours 47 minutes ago

GROUPE SFPI: General management reorganisation
Published on 06/23/2026 at 19:10, 20 hours 25 minutes ago

GUILLEMOT CORPORATION > EVOLUTION DE LA GOUVERNANCE A COMPTER DU 23 JUIN 2026
Published on 06/23/2026 at 19:10, 20 hours 25 minutes ago

GUILLEMOT CORPORATION: Changes to Corporate Governance Effective June 23, 2026

View all LES ECHOS COMFI WIRE